Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    September 2020
  1. GHIRARDI V, Ronsini C, Trozzi R, Di Ilio C, et al
    Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
    Cancer. 2020 Sep 15. doi: 10.1002/cncr.33167.
    PubMed     Abstract available


    August 2020
  2. KIM SR, Tone A, Kim RH, Cesari M, et al
    Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.
    Cancer. 2020 Aug 18. doi: 10.1002/cncr.33144.
    PubMed     Abstract available


    July 2020
  3. CORR BR, Moroney M, Sheeder J, Eckhardt SG, et al
    Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33073.
    PubMed     Abstract available


    June 2020
  4. BLESSING AM, Santiago-O'Farrill JM, Mao W, Pang L, et al
    Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32985.
    PubMed     Abstract available


  5. WESTRICK AC, Bailey ZD, Schlumbrecht M, Hlaing WM, et al
    Residential segregation and overall survival of women with epithelial ovarian cancer.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32989.
    PubMed     Abstract available


    May 2020
  6. PRINTZ C
    Research teams unite to develop an early detection test for ovarian cancer.
    Cancer. 2020;126:2113.
    PubMed    


    February 2020
  7. PRINTZ C
    Study finds that women with posttraumatic stress disorder have an increased risk of ovarian cancer.
    Cancer. 2020;126:468-469.
    PubMed    


  8. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    PubMed     Abstract available


    January 2020
  9. GUO F, Scholl M, Fuchs EL, Berenson AB, et al
    BRCA testing in unaffected young women in the United States, 2006-2017.
    Cancer. 2020;126:337-343.
    PubMed     Abstract available


    December 2019
  10. VERGOTE I, Harter P, Chiva L
    Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Cancer. 2019;125 Suppl 24:4594-4597.
    PubMed     Abstract available


  11. BOOKMAN MA
    Can we predict who lives long with ovarian cancer?
    Cancer. 2019;125 Suppl 24:4578-4581.
    PubMed     Abstract available


  12. AREND R, Martinez A, Szul T, Birrer MJ, et al
    Biomarkers in ovarian cancer: To be or not to be.
    Cancer. 2019;125 Suppl 24:4563-4572.
    PubMed     Abstract available


  13. LEE JM, Minasian L, Kohn EC
    New strategies in ovarian cancer treatment.
    Cancer. 2019;125 Suppl 24:4623-4629.
    PubMed     Abstract available


  14. SEHOULI J, Grabowski JP
    Surgery in recurrent ovarian cancer.
    Cancer. 2019;125 Suppl 24:4598-4601.
    PubMed     Abstract available


  15. PIGNATA S, Pisano C, Di Napoli M, Cecere SC, et al
    Treatment of recurrent epithelial ovarian cancer.
    Cancer. 2019;125 Suppl 24:4609-4615.
    PubMed     Abstract available


  16. FUJIWARA K, Hasegawa K, Nagao S
    Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy.
    Cancer. 2019;125 Suppl 24:4582-4586.
    PubMed     Abstract available


  17. KOOLE SN, van Driel WJ, Sonke GS
    Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Cancer. 2019;125 Suppl 24:4587-4593.
    PubMed     Abstract available


  18. FRIEDLANDER ML
    Do all patients with recurrent ovarian cancer need systemic therapy?
    Cancer. 2019;125 Suppl 24:4602-4608.
    PubMed     Abstract available


  19. GONZALEZ-MARTIN A, Sanchez-Lorenzo L
    Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
    Cancer. 2019;125 Suppl 24:4616-4622.
    PubMed     Abstract available


  20. HARTER P, Heitz F, Ataseven B, Schneider S, et al
    How to manage lymph nodes in ovarian cancer.
    Cancer. 2019;125 Suppl 24:4573-4577.
    PubMed     Abstract available


    November 2019
  21. CRAFTON SM, Cohn DE, Llamocca EN, Louden E, et al
    Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries.
    Cancer. 2019 Nov 27. doi: 10.1002/cncr.32620.
    PubMed     Abstract available


  22. YANG WL, Lu Z, Guo J, Fellman BM, et al
    Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32582.
    PubMed     Abstract available


  23. SANTIAGO-O'FARRILL JM, Weroha SJ, Hou X, Oberg AL, et al
    Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32600.
    PubMed     Abstract available


    August 2019
  24. HAVRILESKY LJ, Yang JC, Lee PS, Secord AA, et al
    Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32447.
    PubMed     Abstract available


  25. MULLINS MA, Peres LC, Alberg AJ, Bandera EV, et al
    Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.
    Cancer. 2019 Aug 15. doi: 10.1002/cncr.32451.
    PubMed     Abstract available


    June 2019
  26. KONDRASHOVA O, Scott CL
    Clarifying the role of EMSY in DNA repair in ovarian cancer.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32135.
    PubMed    


  27. HOLLIS RL, Churchman M, Michie CO, Rye T, et al
    High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079.
    PubMed     Abstract available


    May 2019
  28. KAHN RM, Gordhandas S, Maddy BP, Baltich Nelson B, et al
    Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Cancer. 2019 May 31. doi: 10.1002/cncr.32203.
    PubMed     Abstract available


  29. PINSKY PF, Black A, Daugherty SE, Hoover R, et al
    Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32176.
    PubMed     Abstract available


    March 2019
  30. BAST RC JR, Matulonis UA, Sood AK, Ahmed AA, et al
    Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference.
    Cancer. 2019 Mar 5. doi: 10.1002/cncr.32004.
    PubMed     Abstract available


  31. DE ROOIJ BH, Ezendam NPM, Vos MC, Pijnenborg JMA, et al
    Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery.
    Cancer. 2019;125:788-797.
    PubMed     Abstract available


    January 2019
  32. MAO W, Peters HL, Sutton MN, Orozco AF, et al
    The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31935.
    PubMed     Abstract available


    December 2018
  33. TEMKIN SM, Mallen A, Bellavance E, Rubinsak L, et al
    The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31911.
    PubMed     Abstract available


  34. ESKANDER RN
    Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31902.
    PubMed    


  35. BACKES FJ, Haag J, Cosgrove CM, Suarez A, et al
    Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31901.
    PubMed     Abstract available


    November 2018
  36. LAITMAN Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, et al
    Uterine cancer in Jewish Israeli BRCA1/BRCA2 mutation carriers.
    Cancer. 2018 Nov 29. doi: 10.1002/cncr.31842.
    PubMed     Abstract available


  37. FREY MK, Kopparam RV, Ni Zhou Z, Fields JC, et al
    Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31856.
    PubMed     Abstract available


  38. SMITH HJ, McCaw TR, Londono AI, Katre AA, et al
    The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31761.
    PubMed     Abstract available


    October 2018
  39. HOSKINS KF, Tejeda S, Vijayasiri G, Chukwudozie IB, et al
    A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31635.
    PubMed     Abstract available


    June 2018
  40. ARMER JS, Clevenger L, Davis LZ, Cuneo M, et al
    Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31570.
    PubMed     Abstract available


    February 2018
  41. IYER NS, Cartmel B, Friedman L, Li F, et al
    Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity.
    Cancer. 2018 Feb 13. doi: 10.1002/cncr.31239.
    PubMed     Abstract available


    December 2017
  42. STEWART SL, Harewood R, Matz M, Rim SH, et al
    Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5138-5159.
    PubMed     Abstract available


    November 2017
  43. LUTGENDORF SK, Thaker PH, Arevalo JM, Goodheart MJ, et al
    Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31078.
    PubMed     Abstract available


    September 2017
  44. LE GALLO M, Rudd ML, Urick ME, Hansen NF, et al
    The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30971.
    PubMed     Abstract available


  45. BOBER SL, Recklitis CJ, Michaud AL, Wright AA, et al
    Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30976.
    PubMed     Abstract available


    August 2017
  46. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Abstract available


    July 2017
  47. EVERETT EN
    The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
    Cancer. 2017 Jul 31. doi: 10.1002/cncy.21894.
    PubMed    


  48. TOMAO F, D'Incalci M, Biagioli E, Peccatori FA, et al
    Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30830.
    PubMed     Abstract available


    June 2017
  49. BATEMAN NW, Dubil EA, Wang G, Hood BL, et al
    Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30813.
    PubMed     Abstract available


  50. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    PubMed     Abstract available


    May 2017
  51. SCALICI JM, Arapovic S, Saks EJ, Atkins KA, et al
    Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Cancer. 2017;123:977-984.
    PubMed     Abstract available


  52. LONG ROCHE KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O, et al
    Risk-reducing salpingectomy: Let us be opportunistic.
    Cancer. 2017;123:1714-1720.
    PubMed     Abstract available


  53. BALASUBRAMANIAM S, Kim GS, McKee AE, Pazdur R, et al
    Regulatory considerations on endpoints in ovarian cancer drug development.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30652.
    PubMed     Abstract available


  54. IVY SP, Kohn EC
    Drug development and registration: Challenges and opportunities in ovarian cancer.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30645.
    PubMed    


  55. ZENNARO L, Vanzani P, Nicole L, Cappellesso R, et al
    Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
    Cancer. 2017;125:341-348.
    PubMed     Abstract available


    April 2017
  56. PRINTZ C
    New treatment for patients with advanced ovarian cancer receives accelerated approval.
    Cancer. 2017;123:1286-1287.
    PubMed    


    March 2017
  57. STARK DP, Cook A, Brown JM, Brundage MD, et al
    Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
    Cancer. 2017 Mar 24. doi: 10.1002/cncr.30657.
    PubMed     Abstract available


  58. SAMIMI G, Minasian LM
    Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30525.
    PubMed    


  59. STIEKEMA A, Van de Vijver KK, Boot H, Broeks A, et al
    Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Mullerian origin from gastrointestinal cancer.
    Cancer. 2017;125:197-204.
    PubMed     Abstract available


    February 2017
  60. CRAGUN D, Weidner A, Lewis C, Bonner D, et al
    Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cancer. 2017 Feb 9. doi: 10.1002/cncr.30621.
    PubMed     Abstract available


    January 2017
  61. BUYS SS, Sandbach JF, Gammon A, Patel G, et al
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30498.
    PubMed     Abstract available


    December 2016
  62. GREENWALD ZR, Huang LN, Wissing MD, Franco EL, et al
    Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30529.
    PubMed     Abstract available


  63. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    PubMed    


    November 2016
  64. GANESH K, Shah RH, Vakiani E, Nash GM, et al
    Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Cancer. 2016 Nov 22. doi: 10.1002/cncr.30424.
    PubMed     Abstract available


  65. RUNGRUANG BJ, Miller A, Krivak TC, Horowitz NS, et al
    What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Cancer. 2016 Nov 16. doi: 10.1002/cncr.30414.
    PubMed     Abstract available


    August 2016
  66. RYDZEWSKI NR, Strohl AE, Donnelly ED, Kanis MJ, et al
    Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30228.
    PubMed     Abstract available


    July 2016
  67. DEL CARMEN MG, Supko JG, Horick NK, Rauh-Hain JA, et al
    Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Cancer. 2016 Jul 15. doi: 10.1002/cncr.30196.
    PubMed     Abstract available


    June 2016
  68. GUINDALINI RS, Song A, Fackenthal JD, Olopade OI, et al
    Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Cancer. 2016;122:1913-20.
    PubMed     Abstract available


    May 2016
  69. LIAO ZW, Rodrigues MC, Poynter JN, Amatruda JF, et al
    Risk of second gonadal cancers in women and children with germ cell tumors.
    Cancer. 2016 May 6. doi: 10.1002/cncr.30014.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: